Several analysts have recently updated their ratings and price targets for Climb Bio (NASDAQ: CLYM):
- 8/19/2026 – Climb Bio had its “outperform” rating reaffirmed by Wedbush. They now have a $20.00 price target on the stock.
- 8/7/2026 – Climb Bio had its price target raised by Truist Financial Corporation from $17.00 to $25.00. They now have a “buy” rating on the stock.
- 8/3/2026 – Climb Bio is now covered by Royal Bank Of Canada. They set an “outperform” rating and a $23.00 price target on the stock.
- 8/3/2026 – Climb Bio is now covered by Royal Bank Of Canada. They set a “moderate buy” rating and a $23.00 price target on the stock.
- 7/27/2026 – Climb Bio had its price target raised by Wedbush from $17.00 to $20.00. They now have an “outperform” rating on the stock.
- 7/17/2026 – Climb Bio had its “sell (d-)” rating reaffirmed by Weiss Ratings.
- 6/24/2026 – Climb Bio had its “buy” rating reaffirmed by HC Wainwright. They now have a $20.00 price target on the stock.
Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.
At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.
See Also
- Five stocks we like better than Climb Bio
- Nasdaq’s 23-Hour Trading Push Could Turn Global Liquidity Into a Growth Engine
- Diamondback Hits a Milestone at Just the Right Time
- Analog Devices’ AI Pivot Could Push Shares to Fresh Highs
- One Platform, Every Ailment: Hinge Health’s Gamble
Receive News & Ratings for Climb Bio Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Climb Bio Inc and related companies with MarketBeat.com's FREE daily email newsletter.
